Caplin Point Laboratories (524742) Q2 24/25 earnings summary

Executive summary

• Q2 FY25 revenue grew 17.8%-18% year-over-year, with H1 FY25 revenue up 17%-17.1% YoY, driven by strong performance in both Emerging and US/Regulated markets.

• H1 FY25 PAT surpassed ₹250 Cr for the first time, with Q2 FY25 PAT at ₹130.8-131 Cr, up 12.6%-13% YoY.

• US market revenue for H1 FY25 grew 41% YoY to ₹170 Cr, while Latin America remains the dominant region.

• Maintained a debt-free, cash-positive balance sheet, with free cash reserves at ₹1,039 Cr as of September 30, 2024.

• Focused on long-term projects in oncology, peptides, biosimilars, specialty chemicals, and medical devices, leveraging partnerships in China and Latin America.

Financial highlights

• Q2 FY25 consolidated revenue: ₹483-483.1 Cr (up 17.8%-18% YoY); H1 FY25: ₹942-942.1 Cr (up 17%-17.1% YoY).

• Q2 FY25 PAT: ₹130.8-131 Cr (up 12.6%-13% YoY); H1 FY25 PAT: ₹255.7-256 Cr (up 16% YoY).

• Gross margin for Q2 FY25: 60.9%; EBITDA margin: 36.8%; PAT margin: 26%.

• Free cash flow for H1 FY25: ₹109 Cr; cash and cash equivalents: ₹1,039 Cr.

• Caplin Steriles reported INR 92.42 Cr in operating revenue and INR 12.60 Cr PAC for the quarter.

Outlook and guidance

• Confident in scaling up growth, focusing on larger LatAm markets, US B2C expansion, and new regulated markets (Canada, Australia, MENA, Russia/CIS, Mexico, Brazil).

• US business expected to remain robust as B2B continues, with gradual B2C ramp-up and $100 million US revenue target by FY27/FY28.

• Capacity expansions nearing completion at Puducherry and Vizag API plants, with new product launches planned in US and LatAm.

• Ongoing digitalization of manufacturing and quality systems to enhance compliance.

• New initiatives in specialty products and backward integration to drive long-term growth.